Conversely, biglycan levels showed an increasing trend, being 66.15 ± 2.22 pg/mL in the control group, 70.02 ± 1.57 pg/mL in moderate COVID-19 patients, and 75.88 ± 1.97 pg/mL in severe COVID-19 patients, with an ANOVA p value of 0.0042. The gene discussed is BGN; the disease is COVID-19.